Enhanced recovery after surgery versus conventional approach in peptic perforation- a Randomized Controlled Trial- “ERASE trial”
Abstract
Implementing Enhanced Recovery After Surgery (ERAS) protocol in elective surgeries has improved outcomes. Evidence for a similar role in emergency surgeries must be explored, particularly in patients with peptic perforation. This research aims to study the safety and efficacy of ERAS in patients undergoing surgery for peptic perforation peritonitis. Our study was an open-labeled, randomized, controlled superiority trial conducted on 60 patients of peptic perforation, restricted to first and second category of ASA and distributed equally between the Conventional and ERAS arms. The key interventions in the ERAS arm were intraoperative rectus sheath blockade, encouraging early ambulation, early removal of indwelling catheters and tubes, and early initiation of oral fluid and solid diet. The median length of hospital stay was significantly shorter in the ERAS arm (3 vs 5 days). The patients in the ERAS group were free from all the indwelling catheters within 24 h of the surgery. The time to ambulate (21 h vs 48 h) and initiation of unrestricted clear liquids (after 6 h of surgery) was significantly quicker in the ERAS arm. The surgical site infection (10 vs 5) and pneumonia (5 vs 1) rates were higher in the conventional group. This was clinically significant, even though it failed to attain statistical significance. The comprehensive complication index was significantly higher in the conventional arm. In this study, there was 100% compliance with seven out of eight ERAS…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 60 participants or records.
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.